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1  | INTRODUC TION
This paper is part of a Journal of Neuroscience Research special 
issue published following the International Conference on Brain 
Energy Metabolism hosted by Felipe Barros in Valdivia, Chile, in 
March 2018. The aim of the paper is to draw attention to the contro-
versy on how intramitochondrial 3′,5′‐cyclic adenosine monophos-
phate (cAMP) regulates oxidative phosphorylation (OXPHOS), with a 
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Abstract
Mitochondria produce the bulk of the ATP in most cells, including brain cells. 
Regulating this complex machinery to match the energetic needs of the cell is a com-
plicated process that we have yet to understand in its entirety. In this context, 3′,5′‐
cyclic AMP (cAMP) has been suggested to play a seminal role in signaling-metabolism 
coupling and regulation of mitochondrial ATP production. In cells, cAMP signals may 
affect mitochondria from the cytosolic side but more recently, a cAMP signal pro-
duced within the matrix of mitochondria by soluble adenylyl cyclase (sAC) has been 
suggested to regulate respiration and thus ATP production. However, little is known 
about these processes in brain mitochondria, and the effectors of the cAMP signal 
generated within the matrix are not completely clear since both protein kinase A 
(PKA) and exchange protein activated by cAMP 1 (EPAC1) have been suggested to 
be involved. Here, we review the current knowledge and relate it to brain mitochon-
dria. Further, based on measurements of respiration, membrane potential, and ATP 
production in isolated mouse brain cortical mitochondria we show that inhibitors of 
sAC, PKA, or EPAC affect mitochondrial function in distinct ways. In conclusion, we 
suggest that brain mitochondria do regulate their function via sAC-mediated cAMP 
signals and that both PKA and EPAC could be involved downstream of sAC. Finally, 
due to the role of faulty mitochondrial function in a range of neurological diseases, 
we expect that the function of sAC-cAMP-PKA/EPAC signaling in brain mitochondria 
will likely attract further attention.
K E Y W O R D S
cAMP, EPAC, mitochondria, OXPHOS, PKA, RRID:SCR_002798, RRID:SCR_014526, soluble 
adenylyl cyclase
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specific focus on neurometabolism. To fulfill this aim, this paper is a 
combined review and original paper; hence, the Introduction reviews 
the literature on how intramitochondrial cAMP regulates OXPHOS, 
while the experimental work provides pharmacological results that 
together with the discussion aim to convince peers within the field 
that this controversy deserves to be investigated more thoroughly in 
brain mitochondria.
It is estimated that during rest the human brain consumes 
approximately 20% of total body energy consumption (Mink, 
Blumenschine, & Adams, 1981). Furthermore, it has been estimated 
that 70%–80% of the brain's energy consumption is related to neu-
ronal signaling (Harris, Jolivet, & Attwell, 2012). This high energy 
demand in relation to neuronal signaling suggests that mitochon-
dria in active neurons must be capable of upregulating OXPHOS 
rapidly during neuronal signaling (Howarth, Gleeson, & Attwell, 
2012). Furthermore, mitochondrial dysfunction has been associ-
ated with several neurodegenerative diseases (Correia et al., 2012). 
Hence, understanding the mechanisms of how mitochondria regu-
late OXPHOS is crucial to obtain an in-depth understanding of the 
complexity of neurometabolism. Over the last decade, it has become 
evident that the mitochondrial matrix contains a distinct cAMP mi-
crodomain where cAMP is produced by soluble adenylyl cyclase 
(sAC; Acin-Perez, Salazar, Kamenetsky, et al., 2009; Di Benedetto, 
Gerbino, & Lefkimmiatis, 2018). Several groups have reported that 
intramitochondrial cAMP plays a role in regulating OXPHOS; how-
ever, there is a controversy in the literature on whether this effect 
is mediated via protein kinase A (PKA) or exchange protein directly 
activated by cAMP (EPAC) (e.g., Acin-Perez, Gatti, Bai, & Manfredi, 
2011; Acin-Perez, Salazar, Kamenetsky, et al., 2009; Covian, French, 
Kusnetz, & Balaban, 2014; Wang et al., 2016).
1.1 | cAMP signaling and compartmentalization
The ubiquitous second messenger, cAMP, produced by adenylyl 
cyclase (AC), is known to be involved in regulating numerous cel-
lular functions including, but not limited to, gene transcription, cell 
migration, cell death, and cell metabolism (Horvat & Vardjan, 2018; 
Lefkimmiatis & Zaccolo, 2014). The variety of cAMP responses led 
Buxon and Brunton to suggest that cAMP functions in independent 
microdomains, an idea that is now well established (Buxton & 
Brunton, 1983; Cooper, 2005; Scott, Dessauer, & Taskén, 2013).
The first step to understanding cAMP microdomains starts with 
the variety of ACs. There are nine transmembrane ACs (tmAC 1-9) 
which respond to internal stimuli such as Ca2+ signaling as well as 
receptor-mediated external stimuli (Cooper & Tabbasum, 2014). In 
contrast to the membrane-bound ACs, sAC is found throughout the 
cytosol, as well as associated with or inside several organelles in-
cluding mitochondria and the nucleus (Steegborn, 2014; Wiggins, 
Steegborn, Levin, & Buck, 2018). sAC activity is regulated by bicar-
bonate, Ca2+, and ATP allowing sAC to respond to several cellular 
events including fluctuations in ATP levels or energy metabolism 
(since CO2 produced from TCA cycle activity rapidly is converted 
to bicarbonate via carbonic anhydrase) as well as playing a role in 
Ca2+/cAMP cross-signaling (Buck & Levin, 2011; Chen et al., 2000; 
Litvin, Kamenetsky, Zarifyan, Buck, & Levin, 2003; Steegborn, 2014; 
Steegborn, Litvin, Levin, Buck, & Wu, 2005).
cAMP has four known classes of effectors, PKA, EPAC, cy-
clic nucleotide-gated channels, and the Popeye domain-contain-
ing protein, of which the first two are of interest in this paper. 
Both PKA and EPAC are found throughout the cell and in asso-
ciation with or within several organelles (Cheng, Ji, Tsalkova, & 
Mei, 2008; Lefkimmiatis & Zaccolo, 2014). PKA, believed to be the 
major effector of cAMP, is a serine/threonine kinase (Lefkimmiatis 
& Zaccolo, 2014) and is composed of two catalytic subunits and 
two regulatory subunits, the latter binding cAMP which releases 
the constitutively active catalytic subunits (Cheng et al., 2008). 
PKA is divided into two classes, PKA(I) and PKA(II) with varieties 
in the regulatory subunits (Cheng et al., 2008). Since its discov-
ery two decades ago, EPAC has been associated with an increas-
ing number of cAMP-mediated signaling pathways (Cheng et al., 
2008; Schmidt, Dekker, & Maarsingh, 2013). When activated by 
cAMP, EPAC favors GDP/GTP exchange and thereby activates 
Rap1 and Rap2 that in the cytosol may lead to downstream IP3/
Ca2+ signaling (Schmidt et al., 2013). There are two known iso-
forms of EPAC (EPAC1 and EPAC2) and both are widely distrib-
uted across tissues and cell types (Schmidt et al., 2013). cAMP is 
degraded to AMP by phosphodiesterases (PDEs), a group of en-
zymes consisting of 11 families and almost 100 isoforms (Brescia 
& Zaccolo, 2016; Kokkonen & Kass, 2017). Thus, cAMP signaling 
is terminated by PDE activity, and the many different isoforms, 
many with distinct activators or inhibitors, allow for creating great 
complexity and specific cAMP signaling domains depending on the 
PDEs expressed and/or located to a specific cAMP microdomain. 
In order to form tightly regulated cAMP micodomains, the cAMP 
producing ACs, cAMP effectors, and cAMP degrading PDEs must 
be kept in close spatial connection. A-kinase anchoring proteins 
(AKAPs) have been found throughout the cell and work as scaf-
folding proteins capable of gathering some or all of the above-
mentioned proteins into cAMP microdomains or, more accurately, 
nanodomains (Dessauer, 2009; Dodge‐Kafka et al., 2005; Kritzer, 
Li, Dodge-Kafka, & Kapiloff, 2012; Theurkauf & Vallee, 1982). 
Currently, more than 50 AKAPs are known although only a handful 
Significance
Mitochondrial function is compromised in a range of neu-
rological diseases. sAC-mediated cAMP signaling has been 
suggested to regulate OXPHOS and thus sAC signaling may 
be a putative target for novel pharmacotherapeutic ap-
proaches to restore mitochondrial function. However, sAC 
signaling is severely understudied in relation to brain mi-
tochondria. With this paper, we encourage further studies 
into the functional role of sAC signaling and its downstream 
effectors, PKA and EPAC1, in brain mitochondria in health 
and disease.
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have been studied in detail (see Figure 1a for a cartoon overview 
of cAMP signaling; Dessauer, 2009; Kritzer et al., 2012).
1.2 | Mitochondrial cAMP microdomain(s)
In mammalian cells, the outer mitochondrial membrane (OMM) is 
cAMP permeable, while the inner mitochondrial membrane (IMM) is 
cAMP impermeable (except when mitochondrial permeability transi-
tion (MPT) is induced); as an interesting contrast to this, the IMM in 
Drosophila has repeatedly been shown to be cAMP permeable (Acin-
Perez, Salazar, Kamenetsky, et al., 2009; Di Benedetto et al., 2018; 
Di Benedetto, Scalzotto, Mongillo, & Pozzan, 2013; Lefkimmiatis, 
Leronni, & Hofer, 2013; Zhang et al., 2015). It has been suggested by 
Acin-Perez and colleagues, and later verified by several others, that 
the mitochondrial matrix contains sAC allowing for a mitochondrial 
matrix cAMP signaling domain to exist independently of cytosolic 
cAMP signaling (Acin-Perez, Salazar, Kamenetsky, et al., 2009; Di 
Benedetto et al., 2013; Valsecchi, Konrad, & Manfredi, 2014; Zippin et 
al., 2003). Thus, when considering mitochondrial cAMP signaling, it is 
important to distinguish between the three different cAMP domains, 
mitochondrial matrix, the intermembrane space (IMS), and the OMM 
(Di Benedetto et al., 2018; Monterisi & Zaccolo, 2017).
In support of the existence of cAMP signaling domains in mi-
tochondria, the presence of PKA and possible proteins targeted 
by PKA in the mitochondrial matrix, IMS, and OMM have been re-
ported (reviewed in Di Benedetto et al., 2018; Monterisi & Zaccolo, 
2017). These findings are in line with several studies pointing to a 
large number of possible PKA phosphorylation targets in mitochon-
dria including complex IV (Figure 1b; Grimsrud et al., 2012; Zhao et 
al., 2010). To regulate cAMP-PKA signaling in mitochondria, several 
AKAPs have been reported in mitochondria, most of them associated 
with the OMM and IMM; however, one specific AKAP, sphingosine 
kinase interacting protein (SKIP), was also found in the mitochondrial 
matrix (as reviewed in Monterisi & Zaccolo, 2017; Valsecchi, Ramos-
Espiritu, Buck, Levin, & Manfredi, 2013)). More recently, EPAC1 has 
also been identified in the mitochondrial matrix, suggesting that ma-
trix cAMP signaling is affecting several downstream pathways with 
one suggested target of EPAC1 being the mitochondrial calcium uni-
porter (MCU) (Figure 1b; Qiao, Mei, Popov, Vergara, & Cheng, 2002; 
Wang et al., 2016; Wiggins et al., 2018). PDEA2 has been suggested 
as a main terminator of cAMP signals in the mitochondrial matrix; 
however, other PDEs are likely to play a role (Acin-Perez, Russwurm, 
et al., 2011).
In summary, it seems evident that mitochondria may contain sev-
eral complete and highly regulated cAMP signaling pathways, includ-
ing one localized entirely to the matrix (see Figure 1b for cartoon 
overview of cAMP signaling in the mitochondrial matrix).
1.3 | The role of mitochondrial matrix cAMP 
signaling in regulating OXPHOS
While there is consensus that the cAMP pool in the mitochondrial 
matrix is produced by sAC and is separated from the cAMP pool in 
the cytosol, the downstream effects of this cAMP signaling is highly 
debated with several studies suggesting opposite effects (Acin-Perez, 
Salazar, Kamenetsky, et al., 2009; Covian et al., 2014; Wang et al., 
2016). Part of this disagreement might be caused by a high variety in 
the experimental approaches employed. The effect of mitochondrial 
matrix cAMP has been studied in vitro on isolated proteins, in isolated 
mitochondria, and in intact cells, all from a variety of animal and tissue 
origins. In the following section, focus will be on suggested roles of 
mitochondrial matrix cAMP-mediated regulation of OXPHOS.
F I G U R E  1   cAMP signaling and compartmentalization. (a) Cartoon of cAMP signaling depicting how cAMP is produced by AC (of which 
10 isoforms exist, 9 of them are transmembrane bound; tmAC), degraded by PDE (of which almost 100 isoforms exist) as well as the two 
cAMP effectors PKA (which is divided into two classes) and EPAC (of which two isoforms exist). All of these can be kept in close spatial 
connection by the scaffolding protein AKAP of which more than 50 types are known. Some AKAPs are capable of composing highly complex 
compositions of ACs, effectors, and PDEs to create a specific cAMP microdomain. Cell template is used from http://smart.servi er.com/. 
(b) Cartoon of a mitochondrial matrix cAMP domain. The inner mitochondrial membrane in impermeable to cAMP, thus intramitochondrial 
cAMP signals are produced by intramitochondrial sAC. sAC is activated by bicarbonate, which is in constant equilibrium with CO2 produced 
in the TCA cycle, and by Ca2+. PDEA2 has been identified in the mitochondrial matrix, but other unidentified PDEs are believed to exist 
in the matrix as well. The cAMP effector PKA has been suggested in the mitochondrial matrix, along with several possible PKA phospho-
targets, one of these is Complex IV of the ETC. The cAMP effector EPAC has also been identified in the mitochondrial matrix. At this point 
MCU is the only suggested downstream target of EPAC in the matrix. Both cartoons are based on references found in the introduction 
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In 2009, Acin-Perez and colleagues suggested a CO2-HCO3
−-sAC-
cAMP-PKA-complex IV signaling pathway within the mitochondrial 
matrix based on experiments in isolated mitochondria from mouse 
liver and HeLa cells (Acin-Perez, Salazar, Kamenetsky, et al., 2009). 
The pathway was suggested to be initiated by CO2 produced by the 
TCA cycle which leads to phosphorylation of a complex IV target in-
creasing respiratory capacity, ATP production, and activity of the elec-
tron transport chain (ETC) complexes I, II, and IV (Acin-Perez, Salazar, 
Kamenetsky, et al., 2009). In a series of follow-up studies, the same 
group suggested that the pathway was active in isolated mitochon-
dria from mouse brain (Acin-Perez, Gatti, et al., 2011; Acin-Perez, 
Russwurm, et al., 2011; Acin-Perez, Salazar, Brosel, et al., 2009). 
Furthermore, in mouse fibroblast cells and in mouse liver mitochon-
dria they identified Ser58 of Complex IV‐subunit 1 as the PKA tar-
get, a residue that is conserved among mammals; the phosphorylation 
prevents ATP inhibition of complex IV. Lastly, it was suggested that 
PDE2A is regulating cAMP levels in liver mitochondria, and to some 
extent in brain mitochondria (Acin-Perez, Russwurm, et al., 2011). 
Later, in 2013, Di Benedetto and colleagues (2013) confirmed that the 
mitochondrial matrix contained sAC using a variety of pharmacological 
and genetic tools (siRNA silencing and overexpression). The link be-
tween sAC activity and ATP production was also verified, and PKA was 
suggested as the cAMP effector in this pathway; however, contrary 
to previous reports, they could not increase ATP production with two 
different PKA agonists. Lastly, it was shown in primary cultured neo-
natal rat cardiomyocytes that Ca2+ signaling plays an important role in 
regulating mitochondrial matrix cAMP levels. In 2016, Ramos‐Espiritu 
and colleagues showed that inhibition of sAC in mouse embryo fibro-
blasts led to a decrease in complex IV activity, a decrease that was not 
observed in sAC knockout (KO) cells (Ramos‐Espiritu et al., 2016). One 
year later, Valsecchi and colleagues performed a very elegant study to 
distinguish the roles of cytosolic and mitochondrial sAC in the same 
model system. In sAC KO cells, complex I and complex IV activity as 
well as ATP production, coupled respiration, and membrane potential 
were hampered, and expression of some OXPHOS enzymes were in-
creased. All of these factors were normalized when sAC was expressed 
in the mitochondria. Cytosolic sAC KO caused changes in IP3R signal-
ing which led to changes in ER Ca2+ release (Valsecchi et al., 2017). 
Recently, in a pharmacological characterization of the sAC inhibitors 
2-OHE, KH7 and bithionol, we showed that inhibition of sAC in cere-
bral cortical-isolated mitochondria caused decreased ATP production, 
respiration and membrane potential thus confirming the presence of 
the sAC pathway in brain mitochondria (Jakobsen et al., 2018).
While the work listed above seem to have verified a clear model 
describing a link between mitochondrial matrix cAMP produced by 
sAC and OXHPOS, mediated via PKA, other recent studies seem to 
disagree with the proposed model. In 2013, Lefkimmiatis and col-
leagues verified in HeLA cells that cAMP does not permeate the 
IMM, and that bicarbonate increased cAMP levels in the matrix 
(Lefkimmiatis et al., 2013). However, no PKA activity was observed 
in HeLa or HEK cells, when treated with bicarbonate or a PKA ag-
onist (Lefkimmiatis et al., 2013). Similar results were obtained by 
Burdyga and colleagues who observed no cAMP/PKA-mediated 
phosphorylation in the matrix or IMS but only at the OMM in neona-
tal rat ventricular myocytes (NRVM) and HeLa cells (Burdyga et al., 
2018). Furthermore, Monterisi and colleagues found no presence of 
PDE2A in the mitochondrial matrix, but only at the IMM and OMM 
in NRVM and HeLa cells (Monterisi et al., 2017). In 2016, Wang 
and colleagues verified in isolated rat heart mitochondria that sAC 
produces cAMP in the matrix. The cAMP signal induced increased 
membrane potential, respiration and ATP production; the latter was 
also induced by Ca2+ (Wang et al., 2016). When MPT was induced 
with 10 µM Ca2+, sAC activation by bicarbonate slowed the rate of 
loss in membrane potential, while inhibition of sAC increased the 
rate (Wang et al., 2016). This observation led the authors to suggest 
that sAC-produced cAMP regulates the MCU, which was found to 
be mediated by the cAMP effector EPAC1, and importantly was in-
dependent of PKA activity (Wang et al., 2016). Furthermore, it was 
observed that the EPAC1 inhibitor CE3F4 not only decreased basal 
respiration but also eliminated the HCO3
−-induced increase in respi-
ration (Wang et al., 2016). These findings led the authors to suggest 
that EPAC1 is also involved in regulating OXPHOS in mitochondria 
(Wang et al., 2016). Further, in 2014, Covian and colleagues (2014) 
saw no effect on respiration in pig heart isolated mitochondria when 
stimulating or inhibiting PKA; however, Ca2+ increased the respira-
tion twofold, even in the presence of a PKA inhibitor. In contrast 
to other studies, they found that the cAMP analog 8‐CPT‐6‐Phe‐
cAMP inhibited mitochondrial respiration by decreasing the flow of 
electrons entering ETC, which they argued was due to the lipophilic 
characteristics of the molecule. Furthermore, the study revealed no 
PKA activity in solubilized mitochondria, even in the presence of 
PKA agonists, nor could any PKA subunits be identified in the mi-
tochondria using mass spectrometry. In contrast to this observation, 
Agnes and colleagues showed in isolated mitochondria from bovine 
heart that 85% of mitochondrial PKA was found in the mitochondrial 
matrix (Agnes, Jernigan, Shell, Sharma, & Lawrence, 2010).
As is evident from the above, there is controversy in relation 
to how cAMP produced in the mitochondrial matrix might affect 
OXPHOS. Some of these differences could be related to the variance 
in origin of the cells and mitochondria in which this hypothesis has 
been tested. Both Covian et al. (2014) and Wang et al. (2016) found 
no evidence of PKA activity in heart mitochondria from rat and pig, 
respectively, while Acin-Perez found that OXPHOS in isolated mi-
tochondria from rat and mouse liver and brain were regulated by 
PKA (Acin-Perez, Russwurm, et al., 2011; Acin-Perez, Salazar, Brosel, 
et al., 2009; Acin-Perez, Salazar, Kamenetsky, et al., 2009). Covian 
et al. (2014) argues that the “heart has a significant larger range of 
ATP turnover than the liver or cultured cells,” and that this might 
explain the observed differences in regulation of OXPHOS. In line 
with this argument, mitochondrial heterogeneity in terms of protein 
expression between different organs has previously been reported, 
and could possibly account for some of the observed differences 
(Johnson, Harris, Blair, & Balaban, 2007; Johnson, Harris, French, 
et al., 2007). However, opposite results, for example, observed in 
HeLa and HEK cells by Acin-Perez, Salazar, Kamenetsky, et al. (2009) 
and Lefkimmiatis et al. (2013) might be induced by differences in the 
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experimental design as suggested in the review by Di Benedetto et 
al. (2018).
In summary, the mitochondrial matrix contains a distinct 
cAMP domain, which functions independently of cytosolic cAMP. 
Intramitochondrially produced cAMP likely plays a role in regulating 
OXPHOS. However, the downstream target of cAMP seems to be vari-
able in mitochondria originating from different tissues. The brain is a 
highly energy-demanding organ, and the function and regulation of 
cerebral mitochondria may differ from mitochondria in other tissues. 
To further elucidate and consolidate the role of sAC, PKA, and EPAC1 
in brain energy metabolism, we tested the effects of a variety of sAC, 
PKA and EPAC1 inhibitors on respiration, ATP production and mem-
brane potential in isolated mouse cortical mitochondria.
2  | METHODS
2.1 | Materials
Adenosine‐5′‐diphosphate (ADP, A5285), adenosine‐5′‐triphosphate 
(ATP, A8937), antimycin A (A8674), carbonyl cyanide 4‐(trifluorometh-
oxy)phenylhydrazone (FCCP, C2920), H89 (B1427), LRE‐1 (SML1857), 
malic acid (M1000), oligomycin A (75351), P1,P5‐Di(adenosine‐5′) 
pentaphosphate pentasodium (D4022), pyruvic acid (107360), and 
tetramethylrhodamine methyl ester (TMRM, T5428) were purchased 
from Sigma-Aldrich (St. Louis, MO, USA). CE3F4 (4793) and PKI 14-22 
amide, myristoylated (2546) were purchased from Tocris (Lille, France). 
EPAC 5376753 (10–1564) was from Focus Biomolecules (Plymouth 
Meeting, PA, USA). PercollTM (17–0891-01) was from GE Healthcare 
(Uppsala, Sweden. Luciferin‐luciferase (11‐501) was from BioThema 
AB (Handen, Sweden) and used according to the manufacturer's in-
structions. All other chemicals were of appropriate purity and obtained 
from commercial sources.
2.2 | Animals
Male NMRI mice (Envigo, Cambridgeshire, United Kingdom) aged 
8–9 weeks were housed in a pathogen-free, temperature and hu-
midity-controlled environment at the Department of Drug Design 
and Pharmacology, University of Copenhagen. Mice were handled 
according to standards given by the Danish Animal Experiments 
Inspectorate. The mice were housed in groups of four in individually 
ventilated cages with free access to chow and water. Mitochondrial 
function is affected by sex steroids and the sAC inhibitor 2-hydroxy 
estradiol is an estrogen derivative (Gaignard et al., 2017; Steegborn, 
Litvin, Hess, et al., 2005). Thus, in order to avoid any potential ef-
fects of hormones from female mice being in different stages of the 
estrous cycle, all experiments were performed in male mice, and 
hence sex-specific aspects of the work could not be evaluated.
2.3 | Isolation of brain cortex mitochondria
The isolation procedure was performed on ice or at 4°C as previ-
ously described (Andersen, Christensen, Nissen, & Waagepetersen, 
2017). Mice were euthanized by cervical dislocation, decapitated 
and the brain quickly excised from the cranial vault. Brain cortex 
was excised, transferred to isolation buffer (MSHE; in mM: man-
nitol 210, sucrose 70, HEPES 5, EGTA 1, and 0.5% BSA; pH = 7.2) 
and gently homogenized using a teflon‐on‐glass douncer at 500 
revolutions/min for 7–8 strokes. The homogenate was centrifuged 
(500 g × 5 min) to pellet cell remnants. The supernatant was centri-
fuged (14,000 g × 10 min) and the pellet resuspended in 12% Percoll 
MSHE solution. This suspension was gently layered on a 21% Percoll 
MSHE solution and centrifuged (18,000 g × 15 min). The supernatant 
was discarded and the pellet was washed with two subsequent cen-
trifugations (18,000 g × 5 min and 14,000 g × 5 min) by suspending 
the pellet in MSHE buffer and discarding the supernatant after each 
centrifugation. The final pellet, containing the isolated mitochondria, 
was resuspended and diluted in MSHE and protein amounts were 
determined using the Bradford protein assay with BSA as the refer-
ence protein.
2.4 | Mitochondrial respiration—Seahorse 
XFe96 assay
Respiration of isolated brain cortex mitochondria was monitored 
using a Seahorse XFe96 instrument (Agilent, Santa Clara, USA) 
(Andersen et al., 2017). Mitochondria were isolated as described 
above, diluted to 80 µg protein/ml in respiration buffer (in mM: 
sucrose 250; K2HPO4 15; MgSO4 2; EDTA (free acid) 0.5 and BSA 
0.5 g/L; pH 7.2) and 25 µl was added to each well (2 µg protein/
well) in a 96‐well Seahorse plate. The plate was centrifuged (1,500g 
x 20 min × 4°C) and 155 µl of respiration buffer containing res-
piratory substrates (final concentrations (f.c.) 10 mM pyruvate and 
2 mM malate) and pharmacological compounds, as described, were 
added to each well. The plate was transferred to the XFe96 instru-
ment and the experiment was conducted at 37°C. Mitochondrial 
respiration was monitored as pmol O2/min. Each measurement 
cycle lasted 3 min and was followed by 2 min of mixing plus 1 min 
of rest. Each injection was followed by 1 min of mixing before the 
3 min measurement cycle. After three baseline measurement cy-
cles, ADP (potassium salt, f.c. 4 mM), oligomycin A (f.c. 2.5 µg/
ml; blocking mitochondrial complex V and thus ATP production 
leaving only respiration not driven by ATP synthesis), FCCP (f.c. 
4 µM; uncouples respiration from ATP synthesis and causes near-
maximal respiration), and antimycin A (f.c. 4 µM; blocks transfer 
of electrons from mitochondrial complex III to IV and thus leaves 
only respiration not caused by mitochondria) were injected with a 
measurement cycle following each injection. Two additional meas-
ure cycles were performed after the addition of antimycin A to 
determine the non-mitochondrial respiration. Data were collected 
and extracted using the Wave 2.6.0 software (Agilent, Santa Clara, 
CA, USA; RRID:SCR_014526). All conditions were performed 
with four technical replicates. Basal respiration, state 3 respira-
tion and state 3 uncoupled respiration (pmol O2 consumed/min) 
for each pharmacological condition were normalized to control 
and presented as % of control. Proton leak was calculated as the 
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difference between respiration after injection of oligomycin A and 
respiration after injection of antimycin A, and presented as % of 
control. Respiration control ratio (RCR) was calculated as: (state 3 
respiration—respiration after antimycin A)/proton leak.
2.5 | Mitochondrial ATP synthesis—Luciferin‐
luciferase assay
The procedure is modified from Lanza and Nair (2009) and 
Manfredi, Yang, Gajewski, and Mattiazzi (2002). Mitochondria 
were isolated as described above and diluted to 10 µg protein/
ml in respiration buffer containing respiratory substrates (10 mM 
pyruvate, 2 mM malate and 0.2 µM P1,P5‐Di(adenosine‐5′) pen-
taphosphate pentasodium; the latter was added to inhibit ade-
nylate kinase activity) and pharmacological compounds where 
indicated. ATP production was monitored in a clear bottom 96‐
well plate at 28°C (for optimal luciferin-luciferase response) in a 
NOVOstar microplate reader (BMG Labtech GmbH, Ortenberg, 
Germany) from 2.5 µg mitochondria by injection of 150 µl lucif-
erin‐luciferase and 15 µl hexokinase‐purified ADP (potassium salt; 
to a final concentration of 0.6 mM) to each well and subsequent 
luminescence readings for 38 s followed by injection of 9.62 µM 
ATP (f.c.; potassium salt) as internal standard. As a negative con-
trol, some wells were added 2.5 µg/ml oligomycin A, to inhibit ATP 
synthesis (data not shown). ATP production/(min × mg protein) in 
the presence of the compounds was normalized to the control and 
presented as % of control. All conditions were performed with six 
technical replicates.
2.6 | Mitochondrial membrane potential—
TMRM assay
Mitochondria were isolated as described above. Mitochondrial 
membrane potential (Δψm) was monitored by TMRM (1 µM) fluo-
rescence in quench mode (i.e., the quenching, or decrease, in TMRM 
fluorescence upon uptake into the mitochondria is employed to ap-
proximate changes in the membrane potential) (Nicholls & Ward, 
2000) at 530 nm excitation and 590 nm emission after equilibra-
tion to a stable baseline at 28°C in a NOVOstar microplate reader 
(BMG Labtech GmbH). Measurements were performed in a clear 
bottom 96‐well plate in respiration buffer in the presence of res-
piratory substrates (10 mM pyruvate, 2 mM malate, and 0.2 µM 
P1,P5‐Di(adenosine‐5′) pentaphosphate pentasodium plus 0.6 mM 
ADP) with isolated mitochondria (1 µg/well) and addition of 10 µl 
compound solutions to reach the final concentrations as indicated. 
After 31 min and 36 min oligomycin A (5 µM) and FCCP (4 µM) were 
added, respectively. Measurements of mitochondrial membrane po-
tential are presented as one representative experiment for selected 
conditions. Area under the curve (AUC) was calculated for the inter-
val 10–31 min using GraphPad Prism 7 (RRID:SCR_002798), and the 
conditions with pharmacological treatment were normalized to con-
trol and presented as % of control. All conditions were performed 
with five technical replicates.
2.7 | Analysis and presentation of data
Data shown represent means ± SD (unless otherwise noted), with 
individual data points plotted. Sample sizes were estimated based 
on previous experiments (Andersen, Jakobsen, Waagepetersen, 
& Aldana, 2019; Jakobsen et al., 2018). For each assay, n equals 
the number of experiments where each individual experiment is 
equivalent to a single animal. Seahorse assays were performed as 
six individual experiments. For the ATP and membrane potential 
measurements, all conditions could not be carried out in a single ex-
periment; thus, for each pharmacological condition five experiments 
were conducted (except for EPAC 5376753 5 µM ATP measurement, 
where only four experiments were conducted). Appropriate DMSO 
(solvent of inhibitors) controls were included and are presented as 
an individual data set. Since the DMSO controls were included in 
all experiments and are controls for all the analyzed compounds, 
the DMSO conditions were tested with more experiments than 
the pharmacological compounds. All data were analyzed employing 
GraphPad Prism 8.
All data points (except RCR values) were normalized to the re-
spective controls and presented as % of control. To evaluate the 
effect of DMSO, the DMSO data were compared to 100% (repre-
senting the normalized, blank samples) employing a one-sample t 
test. This test can be used since the test variables are continuous 
and independent, are assumed to be normal distributed and since 
no outliers were found. The RCR values were not normalized to con-
trol since the absolute value of the RCR is of interest. These were 
compared to the raw RCR values of the control employing a one-
way ANOVA with Dunnett's multiple comparisons posttest as were 
samples treated with pharmacological inhibitors (except 2 µM PKI 
which was the only compound containing 0.2% DMSO; data points 
from this condition were compared employing an unpaired t test). 
Data from the pharmacological treatments are assumed to follow a 
normal distribution.
p values < 0.05 are considered significant and are indicated as 
follows: * = p < 0.05; ** = p < 0.01; *** = p < 0.001; **** = p < 0.0001, 
p values < 0.075 are considered as trends. Means, standard devia-
tions, number of biological replicates, and all statistical analyses are 
reported in the data tables (Tables 1‒4).
3  | RESULTS
3.1 | Assessment of solvent effects
Dimethyl sulfoxide (DMSO) was utilized to solubilize the pharmaco-
logical compounds employed in this study, causing final concentra-
tions of DMSO to vary from 0.005% to 0.2%. DMSO has been shown 
to affect metabolism in acute brain slices in concentrations as low as 
0.000025% (Nasrallah, Garner, Ball, & Rae, 2008), and been suggested 
to modify OXPHOS, possibly by changing the kinetics of the ATP syn-
thase (Conover, 1969; de Meis & Suzano, 1988). Furthermore, DMSO 
has been shown to affect membrane permeability enhancement 
(Notman, Noro, O'Malley, & Anwar, 2006). Thus, to assess the effect 
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of DMSO on this preparation of cortical cerebral mitochondria, ATP 
production, oxygen consumption rate (OCR), and membrane potential 
were measured. DMSO caused a small decrease in ATP production 
to around 95% of control; however, only 0.05 and 0.1% DMSO were 
significantly lower than the control (Figure 2a; Table 1). Mitochondrial 
membrane potential was investigated with the dye TMRM in quench 
mode (see the Methods section), and DMSO (0.02%, 0.05%, 0.1% or 
0.2%) had no effect on the membrane potential calculated as AUC 
(ΔΨm(F0/F)) when compared to the control (Figure 2b,+C; Table 1).
Finally, the OCR was investigated employing a Seahorse 
Extracellular Flux analyzer (see the Methods section). DMSO 
(0.2%) significantly decreased baseline respiration to 93.2% of con-
trol (Figure 2d; Table 1). DMSO had no effect on state 3 respiration, 
but 0.2% caused a significant increase in proton leak to 110.6% of 
control (Figure 2e,+F; Table 1). DMSO (0.1 and 0.2%) also induced a 
small decrease in state 3 uncoupled respiration (Figure 2g; Table 1). 
The respiratory control ratio was calculated to 6.89 ± 0.5 for the 
control and DMSO induced no change due to the concentrations 
tested (Figure 2h; Table 1). The observed effects of DMSO showed 
that it was necessary to take these into account when interpreting 
the effect of the pharmacological compounds employed; thus, all 
conditions tested where the drugs are dissolved in DMSO are com-
pared to appropriate DMSO control. An overview of the DMSO 
concentration used in the different conditions can be found in 
Tables 2‒4.
3.2 | Inhibition of sAC decreases mitochondrial 
respiration and ATP production but have little effect 
on membrane potential
Inhibition of mitochondrial sAC with a variety of different inhibi-
tors has been employed widely in the literature (e.g., Acin-Perez, 
Salazar, Kamenetsky, et al., 2009; Di Benedetto et al., 2013). We 
recently published a characterization of some of these inhibitors 
and based on this characterization we decided to employ the newly 
discovered inhibitor LRE-1 (Jakobsen et al., 2018; Ramos-Espiritu 
et al., 2016).
Inhibition of sAC with 5 or 10 µM LRE1 had no effect on ATP 
production, while 25 and 50 µM significantly decreased ATP produc-
tion to 78.5% and 73.2% of control, respectively (Figure 3a; Table 2). 
LRE1 had a small effect on the membrane potential lowering it to 
around 98% of control. Despite the small numerical change, the de-
crease induced by 50 µM was significantly lower than the respective 
DMSO control (Figure 3b,+C; Table 2). LRE1 had no significant effect 
on baseline OCR (Figure 3d; Tables 3,4). LRE1 (50 µM) decreased 
state 3 OCR to 79.4% of control being significantly lower than the 
respective DMSO control (Figure 3e; Table 4), while having no sig-
nificant effect on the proton leak (Figure 3f; Table 3,4). Furthermore, 
25 and 50 µM LRE1 significantly decreased state 3 uncoupled OCR 
to 85.8% and 81.9% of control, respectively (Figure 3g; Table 3,4). 
While LRE1 in concentrations of 5, 10, and 25 µM had no effect on 
RCR, LRE1 50 µM significantly reduced RCR (Figure 3h; Tables 3,4).
3.3 | Inhibition of PKA decreases ATP 
production and membrane potential but have no 
effect on respiration
Several studies have suggested matrix PKA to play a downstream 
role in how sAC regulates OXPHOS (e.g., Acin-Perez, Salazar, 
Kamenetsky, et al., 2009; Di Benedetto et al., 2013). To investi-
gate the role of PKA in regulating cortical cerebral mitochondrial 
function, the commonly used inhibitors of PKA, H89 (0.5, 1 or 
5 µM), and PKI (0.5, 1 or 2 µM) were employed (Dalton & Dewey, 
2006; Lochner & Moolman, 2006). H89 (0.5, 1 or 5 µM) decreased 
ATP production to 91.1%, 72.3%, and 73.2% of control, respec-
tively, the latter two being significantly lower than the respective 
DMSO controls (Figure 4a; Table 2). 1 and 5 µM of H89 signifi-
cantly decreased the membrane potential to 94.0 and 80.5% of 
control, respectively (Figure 4b,+C; Table 2).
H89 had no significant effect on basal OCR, however, 5 µM 
showed a tendency toward decreased basal OCR (Figure 4d; Table 3). 
H89 showed no effect on state 3 OCR, proton leak, state 3 uncou-
pled OCR or RCR values (Figure 4e–h; Table 3).
PKI (0.5, 1, or 2 µM) decreased ATP production to 89.2%, 80.1%, 
and 67.6% of control, respectively, the latter two being significantly 
lower than the respective DMSO controls (Figure 4a; Table 2). In terms 
of membrane potential, PKI (0.5, 1, and 2 µM) significantly decreased 
this to 89.6%, 81.9%, and 77.7% of control, respectively (Figure 4b,+C; 
Table 2). PKI had no effect on basal OCR, state 3 OCR, proton leak, 
state 3 uncoupled OCR or RCR values (Figure 4d–h; Tables 3 and 4).
3.4 | Inhibition of EPAC1 causes dramatic decreases 
in ATP production with relatively smaller effects on 
respiration and membrane potential
The cAMP effector, EPAC, has gained increased attention over the last 
two decades, and EPAC1 has been found inside mitochondria where 
it has been suggested to play a downstream role in how sAC regulates 
OXPHOS (Wang et al., 2016). To investigate the role of EPAC1 in cor-
tical cerebral mitochondrial function, the inhibitors of EPAC1, EPAC 
5376753, and CE3F4 were employed (Brown, Rogers, Aroonsakool, 
McCammon, & Insel, 2014; Courilleau et al., 2012). EPAC 5376753 ( 
5 or 10 µM) significantly decreased ATP production to 12.5% and 
8.5% of control, respectively (Figure 5a; Table 2). EPAC 5376753 
(10 µM) slightly but significantly increased the membrane potential 
(Figure 5b,+C; Table 2). EPAC 5376753 slightly decreased basal OCR 
to 94%–90% of control but only the change induced by 1 µM was sig-
nificantly lower than the respective DMSO control (Figure 5d; Tables 
3 and 4). Further, EPAC 5,376,753 had no effect on state 3 OCR or 
proton leak (Figure 5e–f; Tables 3 and 4). In terms of state 3 uncoupled 
OCR, EPAC 5,376,753 (5 or 10 µM) significantly decreased the OCR 
to 86.3% and 82.3% of control (Figure 5g; Tables 3 and 4). 1 and 5 µM 
EPAC 5,376,753 had no effect on RCR while 10 µM significantly de-
creased RCR to 5.2 (Figure 5h; Tables 3 and 4).
CE3F4 (10, 25, or 50 µM) decreased ATP production to 93.3%, 
78.6%, and 65.6% of control, respectively, with the latter two being 
     |  1029JAKOBSEN Et Al.
F I G U R E  2   Assessment of solvent effects. Oxygen consumption, ATP production, and membrane potential were measured in isolated 
mitochondria of mouse cerebral cortex and challenged with the solvent DMSO (0.02%, 0.05%, 0.1%, or 0.2%) for ATP and membrane 
potential, and DMSO (0.05%, 0.1%, or 0.2%) for OCR measurements. Pyruvate (10 mM) and malate (2 mM) were utilized as substrates and 
all experiments were performed as described in the Methods section. (a) ATP production normalized to control; DMSO 0.02%, n = 4; DMSO 
0.05%, n = 7; DMSO 0.1%, n = 7; DMSO 0.2%, n = 5. (b) Representative trace of membrane potential normalized to baseline measurements 
(0–5.4 min). Vehicle was added after 5.4 min, oligomycin A were added after 31 min, and FCCP were added after 36 min. (c) AUCs of each 
trace in panel B were calculated in the interval from 10–31 min (indicated with dotted lines in panel B) normalized to control; DMSO 0.02%, 
n = 4; DMSO 0.05%, n = 13; DMSO 0.1%, n = 13; DMSO 0.2%, n = 6. (d) Basal respiration normalized to control; n = 6 for all conditions. (e) 
State 3 respiration normalized to control; n = 6 for all conditions. (f) Proton leak normalized to control; n = 6 for all conditions. (g) State 3 
uncoupled respiration normalized to control; n = 6 for all conditions. (h) Respiratory control ratio (RCR); n = 6 for all conditions. Statistics: 
panel a and c–g: one sample t test Panel H: One-way ANOVA with Dunnett's multiple comparisons test; *p < 0.05; **p < 0.01. Means, 
standard deviations, number of biological replicates, and all statistical analyses are reported in Table 1
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F I G U R E  3   Inhibition of sAC decreases mitochondrial respiration and ATP production but have little effect on membrane potential. 
Oxygen consumption, ATP production, and membrane potential were measured in isolated mitochondria of mouse cerebral cortex and 
challenged with the newly developed sAC inhibitor LRE1 (5, 10, 25, or 50 µM). Pyruvate (10 mM) and malate (2 mM) were utilized as 
substrates and all experiments were performed as described in the Methods section. (a) ATP production normalized to control; n = 5 for 
all conditions. (b) Representative trace of membrane potential normalized to baseline measurements (0–5.4 min). Inhibitor or vehicle were 
added after 5.4 min, oligomycin A were added after 31 min, and FCCP were added after 36 min. (c) AUCs of each trace in panel b were 
calculated in the interval from 10–31 min (indicated with dotted lines in panel b) normalized to control; n = 5 for all conditions. (d) Basal 
respiration normalized to control; n = 6 for all conditions. (e) State 3 respiration normalized to control; n = 6 for all conditions. (f) Proton 
leak normalized to control; n = 6 for all conditions. (g) State 3 uncoupled respiration; n = 6 for all conditions. (h) Respiratory control ratio 
(RCR); n = 6 for all conditions. Statistics: One‐way ANOVA with Dunnett's multiple comparisons test; *p < 0.05; **p < 0.01; ***p < 0.001; 
****p < 0.0001. Means, standard deviations, number of biological replicates, and all statistical analyses are reported in Tables 2‒4
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significantly lower than the respective DMSO controls (Figure 5a; 
Table 2). In terms of membrane potential, CE3F4 (10, 25, or 50 µM) 
slightly decreased this to 96%–95% of control, only the latter was 
significantly lower than the respective DMSO control (Figure 5b,+C; 
Table 2). Further, CE3F4 had no effect on basal OCR (Figure 5d; Tables 
3 and 4). CE3F4 significantly increased state 3 OCR to 127%–132% of 
control (Figure 5e; Tables 3 and 4), without having a significant effect 
on proton leak (Figure 5f; Table 3,4). CE3F4 had no effect on state 3 
uncoupled OCR (Figure 5g, Tables 3 and 4). CE3F4 of 10, 25, or 50 µM 
significantly increased RCR to 8.2, 8.2, and 7.9, respectively (Figure 5h; 
Tables 3 and 4).
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4  | DISCUSSION
To our knowledge, the role of intramitochondrial cAMP in regulating 
OXPHOS in cerebral mitochondria only includes three publications 
to this date (Acin-Perez, Russwurm, et al., 2011; Acin-Perez, Salazar, 
Brosel, et al., 2009; Jakobsen et al., 2018). Acin-Perez and colleagues 
reported that in mouse brain mitochondria inhibition of sAC with KH7 
lowers intramitochondrial cAMP levels, ATP production, and respira-
tion (Acin-Perez, Russwurm, et al., 2011; Acin-Perez, Salazar, Brosel, 
et al., 2009). Furthermore, they reported that the cAMP analog 8Br-
cAMP increased ATP production and respiration, while H89 lowered 
ATP production and Complex IV activity (Acin-Perez, Russwurm, et al., 
2011; Acin-Perez, Salazar, Brosel, et al., 2009). Recently, we reported 
that inhibition of sAC in isolated cerebral cortical mitochondria low-
ered ATP production and respiration (Jakobsen et al., 2018).
4.1 | Effect of DMSO on mitochondrial function
In order to separate the effect of the pharmacological treatments and 
the potential effect of DMSO, we assessed the effect of DMSO on 
mitochondrial function in the concentrations employed as vehicles. 
DMSO slightly lowered ATP production, while showing no measurable 
effect on the membrane potential, which could suggest a direct effect 
of DMSO on ATP synthase as suggested previously (de Meis & Suzano, 
1988). DMSO caused a dose-dependent increase in the proton leak, 
which triggered a small nonsignificant decrease in RCR which could be 
explained by DMSO's effect on the permeability of lipid membranes 
(Notman et al., 2006). State 3 respiration were unchanged while basal 
and state 3 uncoupled respiration were lowered at higher DMSO con-
centrations. The latter observations suggest that DMSO has an effect 
either on the TCA cycle or on the ETC independent of its effect on 
ATP synthase.
4.2 | Inhibition of sAC decreases OXPHOS in 
isolated brain cortex mitochondria
Here, we observe that inhibition of sAC by LRE1 lowers mitochon-
drial ATP production and both state 3 and state 3 uncoupled respi-
ration in a dose-dependent manner. This support previous reports 
that mitochondria in the cerebral cortex have an intramitochondrial 
sAC-cAMP-mediated pathway that regulates OXPHOS (Acin-Perez, 
Russwurm, et al., 2011; Acin-Perez, Salazar, Brosel, et al., 2009; 
Jakobsen et al., 2018). Inhibition of sAC with LRE1 caused a small 
decrease in membrane potential, a finding that was also reported by 
Ramos‐Espiritu when applying 50 or 100 µM LRE1 to mouse brain 
mitochondria (Ramos‐Espiritu et al., 2016). We recently showed 
that inhibition of sAC with low concentrations of 2-OHE (10 µM) or 
KH7 (1 µM) had no effect on the membrane potential of isolated 
cerebral cortex mitochondria despite inducing a decrease in ATP 
production and respiration (Jakobsen et al., 2018). In contrast, Acin-
Perez and colleagues showed that inhibition of sAC with 25 µM KH7 
decreased mitochondrial membrane potential (Acin-Perez, Salazar, 
Kamenetsky, et al., 2009); however, several more recent studies 
have revealed that KH7 works as a mitochondrial uncoupler at con-
centrations of above 10 µM (Di Benedetto et al., 2013; Jakobsen et 
al., 2018; Ramos‐Espiritu et al., 2016). Thus, in line with previous 
reports from mouse brain mitochondria, we find that inhibition of 
sAC causes a decrease in OXPHOS in mouse cerebral cortex mito-
chondria. While these results do not reveal any information regard-
ing the downstream pathway that leads to regulation of OXPHOS, 
they provide a novel, valuable pharmacological characterization of 
LRE1’s effects on respiration, membrane potential, and ATP produc-
tion in isolated mouse cerebral cortex mitochondria.
4.3 | Inhibition of PKA decreases ATP 
production and membrane potential without affecting 
respiration in isolated mouse cerebral cortex 
mitochondria
Inhibiting PKA with the selective inhibitor PKI significantly de-
creased ATP production and the membrane potential in a very simi-
lar manner; however, PKI induced no effect on respiration. When 
applying H89, similar responses as those induced by PKI were ob-
served on ATP production and membrane potential. In line with 
this, Acin-Perez and colleagues previously reported that 1 µM H89 
induced a similar decrease in ATP production in isolated brain mi-
tochondria (Acin-Perez, Russwurm, et al., 2011; Acin-Perez, Salazar, 
Brosel, et al., 2009). Similar to what was observed with PKI, H89 
had no significant effect on respiration; however, a high concentra-
tion (5 µM) showed a tendency toward decreased basal respiration. 
A possible explanation for the tendency toward an effect on basal 
respiration observed when applying a high concentration of H89, but 
F I G U R E  4   Inhibition of PKA decreases ATP production and membrane potential without effecting respiration in isolated mouse cerebral 
cortex mitochondria. Oxygen consumption, ATP production, and membrane potential were measured in isolated mitochondria of mouse 
cerebral cortex and challenged with the PKA inhibitors H89 (0.5, 1, or 5 µM) or PKI (0.5, 1, or 2 µM). Pyruvate (10 mM) and malate (2 mM) 
were utilized as substrates and all experiments were performed as described in the Methods section. (a) ATP production normalized to 
control; n = 5 for all conditions. (b) Representative trace of membrane potential normalized to baseline measurements (0–5.4 min). Inhibitor 
or vehicle were added after 5.4 min, oligomycin A were added after 31 min and FCCP were added after 36 min. (c) AUCs of each trace in 
panel B were calculated in the interval from 10–31 min (indicated with dotted lines in panel B) normalized to control; n = 5 for all conditions. 
(d) Basal respiration normalized to control; n = 6 for all conditions. (e) State 3 respiration normalized to control; n = 6 for all conditions. (f) 
Proton leak normalized to control; n = 6 for all conditions. (g) State 3 uncoupled respiration; n = 6 for all conditions. H: Respiratory control 
ratio (RCR); n = 6 for all conditions. Statistics: One‐way ANOVA with Dunnett's multiple comparisons test, except for 2 µM PKI which was 
compared to DMSO 0.2% with an unpaired t test; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. Means, standard deviations, number of 
biological replicates, and all statistical analyses are reported in Tables 2‒4
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F I G U R E  5   Uncompetitive inhibition of EPAC decreases mitochondrial membrane potential leading to downstream effects on ATP 
production and respiration. Oxygen consumption, ATP production, and membrane potential were measured in isolated mitochondria of 
mouse cerebral cortex and challenged with the noncompetitive inhibitor of EPAC1; EPAC 5376753 (1, 5 or 10 µM) or the uncompetitive 
inhibitor CE3F4 (10, 25, or 50 µM). Pyruvate (10 mM) and malate (2 mM) were utilized as substrates and all experiments were performed as 
described in the Methods section. (a) ATP production normalized to control; n = 5 for all conditions, except EPAC 5376753 5 µM with n = 4. 
(b) Representative trace of membrane potential normalized to baseline measurements (0–5.4 min). Inhibitor or vehicle were added after 
5.4 min, oligomycin A were added after 31 min and FCCP were added after 36 min. (c) AUCs of each trace in panel b were calculated in the 
interval from 10–31 min (indicated with dotted lines in panel b) normalized to control; n = 5 for all conditions. (d) Basal respiration normalized 
to control; n = 6 for all conditions. (e) State 3 respiration normalized to control; n = 6 for all conditions. (f) Proton leak normalized to control; 
n = 6 for all conditions. (g) State 3 uncoupled respiration; n = 6 for all conditions. (h) Respiratory control ratio (RCR); n = 6 for all conditions. 
Statistics: One-way ANOVA with Dunnett's multiple comparisons test; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. Means, standard 
deviations, number of biological replicates, and all statistical analyses are reported in Tables 2‒4
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not PKI, could be a non-PKA-mediated effect of H89. H89 has been 
suggested to inhibit at least five other protein kinases with IC50 val-
ues at or below 2.8 µM (Davies, Reddy, Caivano, & Cohen, 2000). 
In the presence of either inhibitor an effect on ATP production and 
membrane potential were observed at concentrations that had no 
effect on state 3 respiration. This observation suggests that PKA 
in cerebral cortical mitochondria can regulate the capacity for ATP 
production potentially by disrupting the membrane potential (and 
thereby lowering the potential for ATP synthesis) independent of 
changes in respiration. PKA-mediated phosphorylation of BCL-2 an-
tagonist of cell death (BAD) is protecting against mitochondrial outer 
membrane permeability by allowing BAD to bind to and thereby 
inhibit BCL-2 (Chipuk & Green, 2008; Lizcano, Morrice, & Cohen, 
2000). The decrease in membrane potential observed when inhibit-
ing PKA, which is independent of changes in OCR, suggest that the 
permeability of the OMM is regulated by PKA activity. This could 
potentially be mediated via the BAD signaling pathway, although this 
cannot be concluded based on the results presented in this study.
Besides the risk of off-target effects, pharmacological inhibition 
of PKA has the pitfall that the inhibitors do not distinguish between 
PKA in the matrix, the IMS, or OMM. Hence, the results presented 
here cannot be employed to conclude that the involved PKA phos-
phorylation sites are found in the matrix. However, as discussed 
above, these results do not support that a PKA phosphorylation tar-
get is able to regulate ETC activity and thereby regulating OXPHOS 
in brain mitochondria as has been suggested for Ser58 on the ma-
trix side of Complex IV-1 in mitochondria from other cells and tissue 
(Acin-Perez, Gatti, et al., 2011).
4.4 | Uncompetitive inhibition of EPAC decreases 
mitochondrial membrane potential possibly  leading 
to downstream effects on ATP production and 
respiration
EPAC1 in mitochondria has gained increased attention recently 
and has been suggested to play a role in regulating MCU activity in 
H295R adrenocortical cells and HeLa cells as well as MCU activity 
and OXPHOS activity in isolated cardiac mitochondria from mouse 
(Szanda, Wisniewski, Rajki, & Spät, 2018; Wang et al., 2016). EPAC1 
has not yet been demonstrated in brain mitochondria (to our knowl-
edge), but here we provide pharmacological evidence for its func-
tional presence.
To assess the effect of EPAC1 in cerebral cortical mitochondria, 
we apply two different inhibitors of EPAC1, the uncompetitive inhib-
itor CE3F4 and the noncompetitive inhibitor EPAC 5376753. We ob-
serve no effect of CE3F4 on basal respiration. However, this may be 
expected since the effect of an uncompetitive inhibitor downstream 
of cAMP may be questionable during baseline respiration since the 
intramitochondrial cAMP levels are expected to be lower due to the 
respiratory control and thereby decreased TCA cycle activity (which 
compared to state 3 respiration leads to less production of CO2→less 
bicarbonate→less sAC activation). When state 3 is induced with 
the presence of ADP (increased TCA cycle activity→increased sAC 
activity→increased concentration of cAMP and thereby inhibition of 
EPAC1 by CE3F4 must be expected), we observe a small decrease in 
membrane potential, which could explain the observed decrease in 
ATP synthesis as well increased state 3 respiration to compensate for 
the decreased membrane potential. This could indicate that EPAC1 is 
involved in regulating the membrane potential which would also ex-
plain why no effect of CE3F4 is observed during state 3 uncoupled 
respiration. These observations suggest an uncoupling effect of CE3F4 
which fulfill two of the three general traits of a mitochondrial uncou-
pler as listed by Terada (1990). However, the lacking increase in base-
line respiration and proton leak strongly indicates that CE3F4 does not 
function as a molecular mitochondrial uncoupler by itself. Wang et al. 
suggest that EPAC1 has an inhibitory effect on MCU in isolated car-
diac mitochondria, and that this mechanism is involved in protecting 
the mitochondria against MPT (Wang et al., 2016). Our experiments 
are performed in the absence of Ca2+ making MCU an unlikely expla-
nation for the observed results; however, the data suggest that EPAC1 
is involved in regulating the mitochondrial membrane potential, poten-
tially via other IMM proton transporters such as uncoupling proteins 
or the adenine nucleotide translocase (Brand et al., 2004).
When applying the noncompetitive inhibitor EPAC 5376753, we 
observed quite different effects compared to what was observed 
with CE3F4. Most strikingly EPAC 5376753 inhibited ATP produc-
tion to the same extent as the inhibitor of ATP synthase oligomycin 
(oligomycin data not shown). This decreased ATP production was not 
similar to the effect observed with LRE1 which suggests three pos-
sible explanations; (i) EPAC 5376753 has a direct effect on the ATP 
synthase; (ii) EPAC1 has a baseline activity in the absence of cAMP 
which can be inhibited to affect ATP synthase; or (iii) EPAC 5376753 
interferes directly with the proton gradient. The latter seem unlikely 
when observing the effect of EPAC 5376753 on membrane poten-
tial and respiration, respectively. A direct effect of EPAC 5376753 
on ATP synthase could explain the observed increase in membrane 
potential as well as the decreased basal and state 3 respiration, but 
does not explain the lowered state 3 uncoupled respiration. The 
seemingly different effects of CE3F4 and EPAC 5376753 suggest 
that either one or both have off-target effects not related to the ef-
fect of EPAC1, which makes the effect of both inhibitors difficult 
to interpret and thus caution should be exercised when employing 
these inhibitors.
4.5 | Future directions
Mitochondrial diversity is reported between species, tissues, and 
even within different regions of the brain (Andersen et al., 2019; 
Johnson, Harris, French, et al., 2007; Phillips et al., 2012). Due to 
this diversity, findings in mitochondria from one tissue should only 
be extrapolated to mitochondria in other tissues if there is experi-
mental data to support it. Based on the current literature and our 
data, we suggest that PKA plays a role in regulating OXPHOS in 
cerebral cortical mitochondria. EPAC1 has not been studied ex-
tensively in isolated mitochondria; however, its suggested effect 
on MCU combined with our results leads to the suggestion that 
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EPAC1 also plays a role in regulating OXPHOS in cerebral corti-
cal mitochondria. While we suggest the relevance of both PKA 
and EPAC1, further studies are needed to verify the downstream 
targets as well as to elaborate on understanding the pathways 
mechanistically.
Intramitochondrial cAMP signaling and its downstream ef-
fects have been studied in either acutely isolated mitochondria 
or cell lines. Working in cell lines provides the advantage of being 
able to express sensors or doing knock out/knock down or over-
expression of proteins of interest (e.g., sAC KO cells and HeLa 
cells expressing a mitochondrial cAMP sensor (Di Benedetto et 
al., 2013; Valsecchi et al., 2017)). However, one concern when 
investigating mitochondria is that cell lines rely more heavily on 
glycolytic metabolism (the Warburg effect and/or the Crabtree 
effect), and thus their mitochondrial regulation must be expected 
to differ compared to what is occurring in the brain and other 
organs highly depending on oxidative metabolism (Diaz-Ruiz, 
Rigoulet, & Devin, 2011; Phillips et al., 2012; Semenza, 2000). 
Thus, working in acutely isolated mitochondria may provide a 
more accurate insight to the function of in situ brain mitochon-
dria with in vivo transfection prior to the isolation procedure 
making it possible to manipulate specific proteins of interest. 
Investigating the mitochondria in primary cultures could for some 
studies be a useful intermediate model system that quite eas-
ily (compared to in vivo) allows for induced expression or knock 
out/knock down of genes while having mitochondria from cells 
not affected by the Warburg–Crabtree effect (Kristián, Hopkins, 
McKenna, & Fiskum, 2006).
The enzymatic activity of sAC is increased by Ca2+ while intra-
mitochondrial cAMP seems to affect Ca2+ levels via EPAC1 and sub-
sequently MCU (Steegborn, 2014; Wang et al., 2016). In line with 
this, it has been reported that rises in mitochondrial Ca2+ increases 
mitochondrial cAMP (Di Benedetto et al., 2013). Due to this Ca2+-
cAMP crosstalk, future studies should address both messengers 
when wishing to investigate the dynamics of either one.
5  | CONCLUSION
Here, we have provided a discussion of the current literature on 
sAC-cAMP-PKA/EPAC signaling in mitochondria and attempted 
to relate this to brain mitochondria. The literature on this issue 
is, however, mostly based on experiments in mitochondria from 
liver or from different non-brain cell lines. To underline the po-
tential importance of this signaling chain in the mammalian brain, 
we support previous observations of how intramitochondrial sAC 
regulates OXPHOS in the brain. Furthermore, we provide pre-
liminary evidence of how PKA affects mitochondrial membrane 
potential and ATP production, seemingly independent of changes 
in ETC activity. Lastly, we suggest that EPAC1 is functionally pre-
sent in brain mitochondria where it might regulate membrane 
potential and thus the capacity for ATP synthesis. Based on this 
and the evidence that mitochondrial malfunction is a hallmark of 
numerous neurological diseases, we strongly encourage further 
research into this important signaling-metabolism coupling in 
brain mitochondria.
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